Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

e print edition of the journal Blood on April 25th, 2013.

David G. Nathan, M.D., president emeritus of the Dana-Farber Cancer Institute, who is the trial's co-lead investigator with Dr. Linden and Joshua Field, M.D., of the BloodCenter of Wisconsin, says he is excited by the prospect of reducing some of the worst symptoms of sickle cell disease, particularly periodic disease exacerbations that lead to severe pain or breathing problems, known as vaso-occlusive crises and acute chest syndrome, respectively. Patients typically do not live beyond their late 40s or early 50s, with pulmonary problems being the most common cause of death.

"Pulmonary complications of sickle cell disease can be fatal because blood flow problems restrict the amount of oxygen going to the lungs," says Dr. Nathan, former physician-in-chief at Boston Children's Hospital and one of the world's top sickle-cell experts. "We are hopeful that the drug will reduce pulmonary injury and extend the lives of sickle cell patients."

In sickle cell anemia, the oxygen-carrying red blood cells become stiff, sticky and misshapen or "sickled" in appearance. This leads to poor blood flow that deprives tissues of oxygen and causes symptoms such as severe pain, difficulty breathing and damage to multiple organs. An inherited disorder, sickle cell anemia occurs in individuals who inherit two copies of the sickle cell geneone from each parent. It is most common in persons of African descent, but is also found in Hispanics of Caribbean ancestry, and people of Middle Eastern, Asian, Indian, Latin American, Native American, and Mediterranean heritage.

"I treat patients with sickle cell anemia in my clinic every day," says Dr. Field. "It is a devastating disease and therapies for the two most common complications, pain and acute chest syndrome, are very limited. Lexiscan has the potential to help people with sickle cell anemia by decreasing the severity of these life-th
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... at Cold Spring Harbor Laboratory (CSHL) is clarifying a ... cancer. Last year, scientists from the same ... protein that changes the instructions for how other proteins ... newly published results show that, in ways not yet ...
... the top priority for the next President will be ... expanding the nation,s commitment to basic scientific research is ... can take to ensure our long-term fiscal health, The ... the moderator of tomorrow,s presidential debate. Answers to ...
... 2008 Putting together the Who,s Who of bats, bears, ... a gigantic task ably assisted by a Field Museum scientific ... and diverse mammal collections. A team headed by the ... comprehensive status on the world,s mammals, including assessments of diversity, ...
Cached Biology News:Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 2The Science Coalition's '10 questions' for the presidential debate 2Field Museum provides gold standard for mammal survey 2Field Museum provides gold standard for mammal survey 3
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is ... the molecular diagnostics industry. BCC Research reveals in its new report that the market ... costs, and a growing need for better diagnostics as part of a molecular diagnostics ...
(Date:7/1/2015)... PALO ALTO, Calif. , July 1, 2015 ... company focused on the development of groundbreaking drugs ... sclerosis (ALS), announced today that Robert G. ... Research Center at Sutter Health,s California Pacific Medical ... from The ALS Association for $1.5 million to ...
(Date:7/1/2015)... 2015 Isagenix International, a leading global health ... three Silver, and three Bronze Stevie® Awards at the ... Chicago this month.The American Business ... program in the U.S. "Winning is ... developing leaders, cultivating talent, creating a unified team, and ...
(Date:7/1/2015)... 2015 InferMed , ... will augment ... clinical s olutions suite   Elsevier ... products and services, announced today the acquisition of  InferMed , ... technology company. InferMed,s Arezzo technology supports clinicians in ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... (Nasdaq: MNKD ) today announced that Matthew ... President and Chief Financial Officer,effective April 21, 2008. ... Chief Operating Officer, and will serve on MannKind,s,executive ... retirement of Dick Anderson, who has now transitioned ...
... (Nasdaq: KOSN ) presented data on its ... of target,specificity, strong binding affinity and potency, a ... and safety in murine xenograft,and orthotopic models., ... stabilize and/or activate a,number of proteins required for ...
... Laboratories, a national,clinical and anatomic pathology reference laboratory and ... that,company co-founder Carl R. Kjeldsberg, MD, will retire as ... Kjeldsberg has held the position,since 1993 and will continue ... Effective, July 1, 2009, Edward R. Ashwood, MD, ...
Cached Biology Technology:Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4ARUP Laboratories CEO and Co-Founder Announces Retirement 2
... CDX2, a member of the caudal-related homeobox ... regulates both proliferation and differentiation in intestinal ... in triggering cells towards the phenotype of ... the maintenance of the phenotype. Clone CDX2-88 ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
Biology Products: